Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Gilead Cites 'More Sophisticated' Process As Pressure For A Major Deal Increases

Executive Summary

CEO John Milligan offered few details about Gilead's deal strategy during an investor conference last week, but analysts think internal pressure for a major deal is beginning to equal the external sentiment, including an analyst who sees Incyte as a likely target, but not a quick fix for Gilead's declining HCV drug sales.

Advertisement

Related Content

Gilead's CEO Gives Glimpse Of Strategic Opportunities As HCV Sales Slide Continues
Deal Watch: Success Nets CytomX Another $200m From BMS, Up To $3.6bn For Milestones
Triple Immunotherapy Combos Enter The Ovarian Cancer Fight
Gilead Admits It Needs M&A To Resume Growth, But Stays Quiet
Gilead Offers Split Guidance For HCV; Expects Further Decline In 2017
Appointments: Shire, Bicycle Therapeutics, Gilead Sciences, Astellas, Alzheon, Alnylam and Amplyx
INFOGRAPHIC: Hepatitis C Market Still Has Room To Grow
When Will Gilead Make Its M&A Move?
Jakafi PV launch pushes up Incyte's 1Q sales

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

SC098426

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel